Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 plus Sintilimab in Advanced Cervical Cancer
NCT04590599Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Dec 2020
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI310 in Cervical Cancer (CC), sponsored by Innovent Biologics. Started Dec 2020; status: completed.
02
Drugs
IBI310
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04590599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590599.